Frontiers in medicine · 2026
Hypoxic preconditioning improves intraoperative oxygenation and postoperative recovery in children undergoing thoracoscopic surgery: a randomized controlled trial.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiao Ting, Wang Lei, Pei Dong Jie, Zhang Shui Bing, Wang Jing Hua, Yang Guang Xian, Qu Shuang Quan
Аннотация
BACKGROUND: Hypoxia preconditioning (HPC) and remote ischemic preconditioning (RIPC) are potential lung-protective strategies, but their efficacy in pediatric thoracic surgery remains unclear. This randomized controlled trial aimed to evaluate the effects of HPC, alone or in combination with RIPC, in children undergoing video-assisted thoracoscopic pulmonary resection.
METHODS: In a single-center, 2 × 2 factorial randomized trial, 160 children (<18 years) undergoing thoracoscopic lung surgery were allocated to four groups: Control (no preconditioning), HPC (three cycles of 5-min hypoxia/ventilation in the non-dependent lung), RIPC (three cycles of 5-min limb ischemia/reperfusion), and combined HPC + RIPC. The primary outcome was the PaO2/FiO2 ratio at 30 min of one-lung ventilation (OLV). Secondary outcomes included the duration of postoperative mechanical ventilation, hospital length of stay, and incidence of postoperative pulmonary complications (PPCs).
RESULTS: A total of 139 patients were included in the final analysis. Compared with the control group, HPC significantly improved oxygenation at 30 min of OLV (PaO2/FiO2: 256.4 ± 60.3 vs. 201.3 ± 65.0 mmHg; p = 0.022), reduced median mechanical ventilation duration (45 vs. 102.5 min; p < 0.001), and shortened hospital length of stay (7 vs. 11 days; p = 0.001). HPC also reduced the incidence of PPCs (53% vs. 81%; p = 0.021), with the largest reduction observed in pleural effusion. The addition of RIPC did not enhance these outcomes, and RIPC alone had no significant effect.
CONCLUSION: HPC was associated with improved intraoperative oxygenation and enhanced postoperative recovery in children undergoing thoracoscopic pulmonary surgery. These findings suggest that HPC may represent a simple and promising lung-protective strategy in pediatric thoracic anesthesia.
CLINICAL TRIAL REGISTRATION: Identifier ChiCTR2000038658, https://www.chictr.org.cn/showproj.html?proj=61845.
METHODS: In a single-center, 2 × 2 factorial randomized trial, 160 children (<18 years) undergoing thoracoscopic lung surgery were allocated to four groups: Control (no preconditioning), HPC (three cycles of 5-min hypoxia/ventilation in the non-dependent lung), RIPC (three cycles of 5-min limb ischemia/reperfusion), and combined HPC + RIPC. The primary outcome was the PaO2/FiO2 ratio at 30 min of one-lung ventilation (OLV). Secondary outcomes included the duration of postoperative mechanical ventilation, hospital length of stay, and incidence of postoperative pulmonary complications (PPCs).
RESULTS: A total of 139 patients were included in the final analysis. Compared with the control group, HPC significantly improved oxygenation at 30 min of OLV (PaO2/FiO2: 256.4 ± 60.3 vs. 201.3 ± 65.0 mmHg; p = 0.022), reduced median mechanical ventilation duration (45 vs. 102.5 min; p < 0.001), and shortened hospital length of stay (7 vs. 11 days; p = 0.001). HPC also reduced the incidence of PPCs (53% vs. 81%; p = 0.021), with the largest reduction observed in pleural effusion. The addition of RIPC did not enhance these outcomes, and RIPC alone had no significant effect.
CONCLUSION: HPC was associated with improved intraoperative oxygenation and enhanced postoperative recovery in children undergoing thoracoscopic pulmonary surgery. These findings suggest that HPC may represent a simple and promising lung-protective strategy in pediatric thoracic anesthesia.
CLINICAL TRIAL REGISTRATION: Identifier ChiCTR2000038658, https://www.chictr.org.cn/showproj.html?proj=61845.